Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes Mellitus and Moderate to Severe Renal Impairment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Lexicon Pharmaceuticals
- 01 Oct 2013 Results have been reported in a Lexicon Pharmaceuticals media release.
- 01 Oct 2013 Primary endpoint 'Postprandial-glucose-level' has been met according to a Lexicon Pharmaceuticals media release.
- 31 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.